Penicillamine-induced ocular myasthenia gravis in rheumatoid arthritis.
We report a case of a 47-year-old woman with rheumatoid arthritis who developed ocular myasthenia gravis during penicillamine treatment. Her serum contained elevated titers of acetylcholine receptor antibodies, and her symptoms resolved 8 weeks after discontinuation of penicillamine. We review the clinical and laboratory features of this syndrome of penicillamine-induced myasthenia gravis and discuss its pathophysiology and treatment.
Liu
G T
GT
Division of Neurology, Brigham and Women's Hospital, Boston, MA 02115.
Bienfang
D C
DC
D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D004172:Diplopia / Q000139:chemically induced / Q000150:complications / Q000503:physiopathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology; D015835:Ocular Motility Disorders / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology; D009801:Oculomotor Muscles / Q000187:drug effects; D010396:Penicillamine / Q000009:adverse effects*; D011950:Receptors, Cholinergic / Q000097:blood
D011950:Receptors, Cholinergic; D010396:Penicillamine